Gilead Slaps Mega-Price on Its Newly Approved CAR-T
Gilead Sciences (NASDAQ: GILD) recently acquired clinical-stage CAR-T drugmaker Kite Pharma, for $11.9 billion and on Wednesday, the FDA helped validate the company's purchase price by approving Yescarta more than one month ahead of schedule.
The approval makes Yescarta only the second drug from an entirely new class of cancer killers to get the regulatory nod and Yescarta's $373,000 price tag suggests it could meaningfully offset Gilead Sciences' declining hepatitis C drug revenue next year.
Image source: Getty Images.
Source: Fool.com
Novartis AG ADR Stock
€136.00
-
With 11 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 150 € there is a slightly positive potential of 10.29% for Novartis AG ADR compared to the current price of 136.0 €.
